Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
21 mars 2024 16h05 HE
|
Senti Biosciences, Inc.
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...
(SPAC) Special Purpose Acquisition Investigation: BBAI, TNGX, SNTI, GMTX, Contact Shareholder Rights Law Firm Johnson Fistel
26 mai 2023 12h26 HE
|
Johnson Fistel, LLP
SAN DIEGO, May 26, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection with the following special purpose acquisition...